Minute Insight: Angle’s Parsortix Gets FDA Approval, Marking New Era For Liquid Biopsy
The FDA has approved Angle’s Parsortix circulating tumor cell cancer capturing system, which the company believes will be a paradigm shift for liquid biopsy in the US and heighten competition in the oncology diagnostics space.
You may also be interested in...
Epic Sciences Talks Differentiation And Benefits Of Its DefineMBC Cancer Test
Epic Sciences spoke to Medtech Insight to discuss the development of its DefineMBC test for metastatic breast cancer.
Report Digest: Tackling The Liquid Biopsy For Oncology Market With An Expert
In this first edition of Report Digest, UK-based reporter Barnaby Pickering discusses the liquid biopsy for oncology market with analyst Phil Greenfield. The two discuss the main market drivers and what experts think will occur in the sector in future years.
Angle Will Reshape Liquid Diagnostics By Capturing Circulating Tumor Cells
Following a successful fundraise, Angle is poised to further commercialize its proprietary cell-catching technology for cancer diagnosis